Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum KY1032
- Development stage
- Preclinical
- Lead developer
- Hy Co
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum KY1032 is a specific probiotic strain developed by the Korean company hy Co., Ltd., and isolated from kimchi. [25, 28] It is most frequently studied and marketed in a combination product with *Lactobacillus curvatus HY7601* for its effects on metabolic health. [18] Research, including preclinical studies and human clinical trials, has investigated its potential to manage overweight and obesity, hypertriglyceridemia, and age-related cognitive decline. The proposed mechanisms of action include the modulation of the gut microbiota, inhibition of adipogenesis (fat cell formation) by downregulating key transcription factors like PPAR-γ, and improving lipid metabolism by upregulating the expression of apolipoprotein A-V (ApoA-V), PPARα, and FXR. [21554138, 23555678, 26117402, 26699746] It is administered orally, typically as a powder or in a capsule. [26044516, 35745214]
- Other names
- KCCM-10430KCCM10430KCCM 10430
02
Targets
FASN (Fatty acid synthase)FABP4 (Fatty acid-binding protein 4)PPARG (Peroxisome proliferator-activated receptor gamma)CEBPA (CCAAT enhancer-binding protein alpha)
Beyond the preview
Go deeper on Lactobacillus plantarum KY1032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum KY1032.